Piper Sandler Highlights Century Therapeutics (IPSC) Cash Runway Through 2029, Upcoming IND Submission

Group 1 - Century Therapeutics Inc. (NASDAQ:IPSC) is recognized as a fast-growing penny stock, with analysts highlighting its potential for investment [1] - Piper Sandler raised its price target for Century Therapeutics to $4 from $2, citing the company's plan to submit an IND for CNTY-813 this year and deliver initial data by 2027 [1] - The company has a strong financial position, with an estimated pro forma cash balance of approximately $267 million, expected to fund operations through Q1 2029 [1] Group 2 - Clear Street analyst Bill Maughan reduced the price target for Century Therapeutics to $6.60 from $8 while maintaining a Buy rating, noting that a recent private placement extends the company's cash runway into Q1 2029 [2] - The reduction in price target by Clear Street accounts for dilution from the capital raise but is offset by an increased likelihood of pipeline success and higher projected peak sales [3] - Century Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic cell therapies for solid tumors, hematological malignancies, and autoimmune diseases [4]